Genmab — Marts 2012
-
ofatumab 220 mill r&d
-
Arzerra. Vi har regular commercial updates med GSK
-
Og det er et internal number
-
Edison Investment:
-
Vi regner med Partnerskab på dara og de er under CDA med several parties og interessen er "skyhigh"
-
It ticks all the boxes of what pharma wants to see
-
market er 3,9 milliader
-
det er muligt at partner stoffet i 2012 og det har højeste prioritet.
-
De behøver ikke at bevæge det klinisk fremad fra nu for at indgå en aftale
-
de vil have en stor partner. Upfront milestones + royalties
-
revenue guidance: arzerra + deferred income?
-
og så lidt om daratumumab
-
hvad kigger partnerne på ? hvad siger de? er data klar?
-
number of cda parties stiger for hver uge
-
pretty high intensity now
-
rigtigt deferred er 226, + arzerra 90-100 + 40 klinisk reimbursement
-
Så er der Nordea
-
national reimbursement i 7 lande
-
og j-code i usa
-
et new territorie (red. asien eller japan)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind